Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OKI-219

Small molecule · Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA) · developed by OnKure

Phase 1 Most advanced trial
OKUR Developer
1 Registered trials

What is OKI-219?

OKI-219 is an orally bioavailable, mutant-selective inhibitor of the PIK3CA H1047R mutant form of the PI3K p110alpha catalytic subunit. It blocks PI3K/Akt/mTOR signaling in PIK3CA H1047R-mutant tumor cells, and it is studied in advanced cancer, breast cancer, and advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA)
Mechanism
Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA)
Pathways
PI3K/Akt/mTOR pathway, apoptosis, growth inhibition
Therapy area
Oncology
Developer
OnKure, Inc. (OKUR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06239467 Phase 1 Advanced Cancer Active not recruiting OKUR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerAdvanced Solid TumorsBreast CancerPI3K Gene Mutation

Other drugs acting on PIK3CA

More from OnKure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OKUR page.

Follow OKUR, the company behind OKI-219

See OKUR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OKUR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.